Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹2,281 Cr revenue.
COGS 35.5%, employees 16.3%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 17.2%▲ | 10.5% |
| ROCE | 22.9%▲ | 13.8% |
| Net Margin | 26.7%▲ | 8.7% |
| EBITDA Margin | 38.5%▲ | 16.0% |
| Debt To Equity | 0.00x▼ | 0.21x |
Historical valuation data not available.
Revenue segment breakdown not available.
| (₹ Cr) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹2,281 Cr +4.0% | ₹2,193 Cr -9.6% | ₹2,425 Cr -7.1% | ₹2,611 Cr +16.6% | ₹2,239 Cr +4.0% | ₹2,152 Cr +3.4% | ₹2,082 Cr |
| Other Income | ₹172 Cr -4.6% | ₹181 Cr +78.6% | ₹101 Cr +61.3% | ₹63 Cr -22.8% | ₹81 Cr -55.9% | ₹184 Cr +9.9% | ₹167 Cr |
| Total Income | ₹2,454 Cr +3.4% | ₹2,374 Cr -6.0% | ₹2,526 Cr -5.5% | ₹2,674 Cr +15.3% | ₹2,320 Cr -0.7% | ₹2,336 Cr +3.9% | ₹2,249 Cr |
| COGS | ₹810 Cr +2.3% | ₹793 Cr -9.3% | ₹874 Cr -7.8% | ₹948 Cr +18.8% | ₹798 Cr +0.7% | ₹792 Cr +5.9% | ₹748 Cr |
| ₹1,610 Cr -1.5% | ₹1,636 Cr -5.7% | ₹1,735 Cr -8.7% | ₹1,901 Cr +15.1% | ₹1,651 Cr -2.5% | ₹1,693 Cr +6.6% | ₹1,589 Cr | |
| Profit Before Tax | ₹1,016 Cr +36.2% | ₹746 Cr -9.5% | ₹824 Cr +6.6% | ₹773 Cr +15.6% | ₹669 Cr +4.1% | ₹642 Cr -2.6% | ₹660 Cr |
| Exceptional Items | ₹173 Cr | ₹8 Cr -75.9% | ₹33 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| ₹248 Cr +27.6% | ₹195 Cr -2.7% | ₹200 Cr +24.8% | ₹160 Cr -6.3% | ₹171 Cr +28.3% | ₹133 Cr -42.2% | ₹231 Cr | |
| Net Profit | ₹768 Cr +39.2% | ₹551 Cr -11.6% | ₹624 Cr +1.9% | ₹613 Cr +23.1% | ₹498 Cr -2.3% | ₹509 Cr +18.7% | ₹429 Cr |
| Other Comprehensive Income | ₹0.74 Cr -86.4% | ₹5 Cr +51.0% | ₹4 Cr -49.7% | ₹7 Cr ↑ Recovery | (₹0.96 Cr) +89.2% | (₹9 Cr) ↓ Decline | ₹1 Cr |
| EPS | ₹167.79 | ₹120.52 | ₹136.38 | ₹133.90 | ₹108.77 | ₹111.29 | ₹93.79 |
| Diluted Shares | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
No earnings call transcripts available.
Pfizer Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 20...
Pfizer Limited has informed the Exchange about Copy of Newspaper Publication
Pfizer Limited has informed the Exchange about Delay/default in the payment of fines/penalties/dues etc. to authority
Pfizer Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Pfizer Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
Pfizer Limited has informed the Exchange about Copy of Newspaper Publication
Pfizer Limited has informed the Exchange about change in Management
Pfizer Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
The Exchange has sought clarification from Pfizer Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201...
Pfizer Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Pfizer Limited has informed the Exchange about Action(s) initiated or orders passed
Pfizer Limited has informed the Exchange about Action(s) taken or orders passed
Pfizer Limited has informed the Exchange about change in Management
Pfizer Limited has informed the Exchange regarding a press release dated December 19, 2025, titled "Exclusive Supply and Marketing Agreement for Pfizer Limited s brands Corex Dx,Corex LS, Dolonex, a...
Pfizer Limited has informed the Exchange about Arrangements for strategic, technical, manufacturing, or marketing tie up
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.